Zijiao Zou

Zijiao Zou


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
JTJessica Oi-Ling Tsang
Jessica Oi-Ling Tsang
JZJie Zhou
Jie Zhou
ZXZHAO XIAOYU
ZHAO XIAOYU
CLCun Li
Cun Li
ZZZijiao Zou
Zijiao Zou
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
Enteroviruses are important causes of hand, foot, and mouth disease, respiratory infections, and neurological infections in human. A major hurdle for the development of anti-enterovirus agents is the lack of physiologically relevant evaluation platforms that closely correlate with the in vivo state. We established the human small intestinal organoids as a novel platform for characterizing the viral replication kinetics and evaluating candidate antivirals for enteroviruses. The organoids supported productive replication of enterovirus (EV)-A71, coxsackievirus B2, and poliovirus type 3, as evidenced by increasing viral loads, infectious virus titers, and the presence of cytopathic effects. In contrast, EV-D68, which mainly causes respiratory tract infection in humans, did not replicate significantly in the organoids. The differential expression profiles of the receptors for these enteroviruses correlated with their replication kinetics. Using itraconazole as control, we showed that the results of various antiviral assays, including viral load reduction, plaque reduction, and cytopathic effect inhibition assays, were highly reproducible in the organoids. Moreover, itraconazole attenuated virus-induced inflammatory response in the organoids, which helped to explain its antiviral effects and mechanism. Collectively, these data showed that the human small intestinal organoids may serve as a robust platform for investigating the pathogenesis and evaluating antivirals for enteroviruses.

23 July 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
ZZZijiao Zou
Zijiao Zou
JTJessica Oi-Ling Tsang
Jessica Oi-Ling Tsang
Bingpeng YANBingpeng YAN
Bingpeng YAN
KCKenn Ka-Heng Chik
Kenn Ka-Heng Chik
CCChris Chun Yiu Chan
Chris Chun Yiu Chan
KYKwok-Yung Yuen
Kwok-Yung Yuen
Enterovirus A71 (EV-A71) is a common cause of hand, foot, and mouth disease. Severe EV-A71 infections may be associated with life-threatening neurological complications. However, the pathogenic mechanisms underlying these severe clinical and pathological features remain incompletely understood. Metabolites are known to play critical roles in multiple stages of the replication cycles of viruses. The metabolic reprogramming induced by viral infections is essential for optimal virus replication and may be potential antiviral targets. In this study, we applied targeted metabolomics profiling to investigate the metabolic changes of induced pluripotent human stem cell (iPSC)-derived neural progenitor cells (NPCs) upon EV-A71 infection. A targeted quantitation of polar metabolites identified 14 candidates with altered expression profiles. A pathway enrichment analysis pinpointed glucose metabolic pathways as being highly perturbed upon EV-A71 infection. Gene silencing of one of the key enzymes of glycolysis, 6-phosphofructo-2-kinase (PFKFB3), significantly suppressed EV-A71 replication in vitro. Collectively, we demonstrated the feasibility to manipulate EV-A71-triggered host metabolic reprogramming as a potential anti-EV-A71 strategy.

27 August 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BHBodan Hu
Bodan Hu
KCKenn Ka-Heng Chik
Kenn Ka-Heng Chik
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
JCJianpiao Cai
Jianpiao Cai
HCHehe Cao
Hehe Cao
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
Enterovirus A71 (EV-A71) infection is a major cause of hand, foot, and mouth disease (HFMD), which may be occasionally associated with severe neurological complications. There is currently a lack of treatment options for EV-A71 infection. The Raf-MEK-ERK signaling pathway, in addition to its critical importance in the regulation of cell growth, differentiation, and survival, has been shown to be essential for virus replication. In this study, we investigated the anti-EV-A71 activity of vemurafenib, a clinically approved B-Raf inhibitor used in the treatment of late-stage melanoma. Vemurafenib exhibits potent anti-EV-A71 effect in cytopathic effect inhibition and viral load reduction assays, with half maximal effective concentration (EC50) at nanomolar concentrations. Mechanistically, vemurafenib interrupts both EV-A71 genome replication and assembly. These findings expand the list of potential antiviral candidates of anti-EV-A71 therapeutics.

25 July 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
BHBodan Hu
Bodan Hu
KCKenn Ka-Heng Chik
Kenn Ka-Heng Chik
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
JCJianpiao Cai
Jianpiao Cai
JTJessica Oi-Ling Tsang
Jessica Oi-Ling Tsang
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
Enterovirus A71 (EV-A71) infection is a major cause of hand, foot and mouth disease (HFMD) which may be occasionally associated with severe neurological complications. There are currently a lack of treatment options for EV-A71 infection. The Raf-MEK-ERK signaling pathway, in addition to its critical importance in the regulation of cell growth, differentiation and survival, has been shown to be essential for virus replication. In this study, we investigated the anti-EV-A71 activity of vemurafenib, a clinically approved B-Raf inhibitor used in the treatment of late stage melanoma. Vemurafenib exhibits potent anti-EV-A71 effect in cytopathic effect inhibition and viral load reduction assays, with half maximal effective concentration (EC50) at nanomolar concentration. Mechanistically, vemurafenib interrupts both EV-A71 genome replication and assembly. These findings expand the list of potential antiviral candidates of anti-EV-A71 therapeutics.